The Prognostic Significance of Peroxisome Proliferator-activated Receptor β Expression in the Vascular Endothelial Cells of Colorectal Cancer

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2013 Jul 4

PMID 23821017

Citations 4

Authors

Jin Zhou

Lie Yang

Yuan Li

Gunnar Arbman

Ke-Ling Chen

Bin Zhou

Yong-Yang Yu

Cun Wang

Xian-Ming Mo

You Lu

Zong-Guang Zhou

Xiao-Feng Sun

Affiliations

Soon will be listed here.

Abstract

Objective: Currently, little is known regarding the role of peroxisome proliferator-activated receptor-β (PPAR β) in the vascular endothelial cells (VECs) of colorectal cancers (CRCs). The aim of this study was to investigate the relationship of PPAR β expression in the VECs of CRCs in terms of the prognosis and clinicopathological features of CRC patients.

Design: The expression and localization of PPAR β in the primary cancers and the matched normal mucosal samples of 141 Swedish CRC patients were analyzed in terms of its correlation with clinicopathological features and the expression of angiogenesis-related genes. This study also included 92 Chinese CRC patients.

Results: PPAR β was predominantly localized in the cytoplasm and was significantly downregulated in the VECs of CRC compared to that of the normal mucosa. The low expression levels of PPAR β in the VECs of CRC were statistically correlated with enhanced differentiation, early staging and favorable overall survival and were associated with the increased expression of VEGF and D2-40. The patients exhibiting elevated expression of PPAR β in CRC cells but reduced expression in VECs exhibited more favorable survival compared with the other patients, whereas the patients with reduced expression of PPAR β in CRC cells but increased expression in VECs exhibited less favorable prognosis.

Conclusions: PPAR β might play a tumor suppressor role in CRC cells in contrast to a tumor promoter role in the VECs of CRCs.

Citing Articles

Peroxisome proliferator-activated receptors regulate the progression and treatment of gastrointestinal cancers.

Zhang M, He S Front Pharmacol. 2023; 14:1169566.

PMID: 37025484 PMC: 10070695. DOI: 10.3389/fphar.2023.1169566.

Knockdown of PPARδ Induces VEGFA-Mediated Angiogenesis Interaction With ERO1A in Human Colorectal Cancer.

Luo W, He D, Zhang J, Ma Z, Chen K, Lv Z Front Oncol. 2021; 11:713892.

PMID: 34712608 PMC: 8546184. DOI: 10.3389/fonc.2021.713892.

A primary tumor gene expression signature identifies a crucial role played by tumor stroma myofibroblasts in lymph node involvement in oral squamous cell carcinoma.

Mazzoccoli G, Castellana S, Carella M, Palumbo O, Tiberio C, Fusilli C Oncotarget. 2017; 8(62):104913-104927.

PMID: 29285222 PMC: 5739609. DOI: 10.18632/oncotarget.20645.

Colorectal cancer prognosis and PPARδ/β expression in the tumor microenvironment.

Mazzoccoli G J Gastroenterol. 2013; 49(3):564-5.

PMID: 24277053 DOI: 10.1007/s00535-013-0913-z.

References

Yang L, Olsson B, Pfeifer D, Jonsson J, Zhou Z, Jiang X . Knockdown of peroxisome proliferator-activated receptor-beta induces less differentiation and enhances cell-fibronectin adhesion of colon cancer cells. Oncogene. 2009; 29(4):516-26. DOI: 10.1038/onc.2009.370. View

Wang D, Wang H, Guo Y, Ning W, Katkuri S, Wahli W . Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A. 2006; 103(50):19069-74. PMC: 1748178. DOI: 10.1073/pnas.0607948103. View

Kilgore K, Billin A . PPARbeta/delta ligands as modulators of the inflammatory response. Curr Opin Investig Drugs. 2008; 9(5):463-9. View

Yang L, Zhang H, Zhou Z, Yan H, Adell G, Sun X . Biological function and prognostic significance of peroxisome proliferator-activated receptor δ in rectal cancer. Clin Cancer Res. 2011; 17(11):3760-70. DOI: 10.1158/1078-0432.CCR-10-2779. View

Piqueras L, Reynolds A, Hodivala-Dilke K, Alfranca A, Redondo J, Hatae T . Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol. 2006; 27(1):63-9. DOI: 10.1161/01.ATV.0000250972.83623.61. View

He T, Chan T, Vogelstein B, Kinzler K . PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999; 99(3):335-45. PMC: 3779681. DOI: 10.1016/s0092-8674(00)81664-5. View

Takayama O, Yamamoto H, Damdinsuren B, Sugita Y, Ngan C, Xu X . Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br J Cancer. 2006; 95(7):889-95. PMC: 2360534. DOI: 10.1038/sj.bjc.6603343. View

Zhang Z, Tian Y, Wang Y, Zhang L, Zhao Z, Sun X . PINCH mRNA overexpression in colorectal carcinomas correlated with VEGF and FAS mRNA expression. Anticancer Res. 2011; 31(12):4127-33. View

Varnat F, Heggeler B, Grisel P, Boucard N, Corthesy-Theulaz I, Wahli W . PPARbeta/delta regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterology. 2006; 131(2):538-53. DOI: 10.1053/j.gastro.2006.05.004. View

10.

Romero S, Szafranska J, Cabrera E, Gonzalez A, Peiro A, Llauger J . Role of tumor-associated macrophages and angiogenesis in desmoid-type fibromatosis. Virchows Arch. 2012; 461(2):117-22. DOI: 10.1007/s00428-012-1265-4. View

11.

Harman F, Nicol C, Marin H, Ward J, Gonzalez F, Peters J . Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med. 2004; 10(5):481-3. DOI: 10.1038/nm1026. View

12.

Desvergne B, Michalik L, Wahli W . Transcriptional regulation of metabolism. Physiol Rev. 2006; 86(2):465-514. DOI: 10.1152/physrev.00025.2005. View

13.

Rohrl C, Kaindl U, Koneczny I, Hudec X, Baron D, Konig J . Peroxisome-proliferator-activated receptors γ and β/δ mediate vascular endothelial growth factor production in colorectal tumor cells. J Cancer Res Clin Oncol. 2010; 137(1):29-39. DOI: 10.1007/s00432-010-0856-1. View

14.

Muller-Brusselbach S, Komhoff M, Rieck M, Meissner W, Kaddatz K, Adamkiewicz J . Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice. EMBO J. 2007; 26(15):3686-98. PMC: 1949001. DOI: 10.1038/sj.emboj.7601803. View

15.

Gao J, Arbman G, Rearden A, Sun X . Stromal staining for PINCH is an independent prognostic indicator in colorectal cancer. Neoplasia. 2005; 6(6):796-801. PMC: 1531683. DOI: 10.1593/neo.04304. View

16.

Molnar F, Matilainen M, Carlberg C . Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators. J Biol Chem. 2005; 280(28):26543-56. DOI: 10.1074/jbc.M502463200. View

17.

Muller R, Rieck M, Muller-Brusselbach S . Regulation of Cell Proliferation and Differentiation by PPARbeta/delta. PPAR Res. 2008; 2008:614852. PMC: 2542843. DOI: 10.1155/2008/614852. View

18.

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

19.

Sun X, Zhang H . Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas. Mol Cancer. 2006; 5:43. PMC: 1618857. DOI: 10.1186/1476-4598-5-43. View

20.

Jakob C, Aust D, Liebscher B, Baretton G, Datta K, Muders M . Lymphangiogenesis in regional lymph nodes is an independent prognostic marker in rectal cancer patients after neoadjuvant treatment. PLoS One. 2011; 6(11):e27402. PMC: 3210168. DOI: 10.1371/journal.pone.0027402. View